Sweet K - Search Results

1

Can increased immunogenicity in chronic myeloid leukemia improve outcomes?

Chan O, Talati C, Sweet K, Pinilla-Ibarz J. Chan O, et al. Among authors: sweet k. Expert Rev Hematol. 2019 Apr;12(4):225-233. doi: 10.1080/17474086.2019.1588105. Epub 2019 Mar 11. Expert Rev Hematol. 2019. PMID: 30855193 Review.

2

Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison.

Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ, Sokol L, Lancet J, Tinsley S, Sweet K, Komrokji R, Jacobsen PB. Phillips KM, et al. Among authors: sweet k. Support Care Cancer. 2013 Apr;21(4):1097-103. doi: 10.1007/s00520-012-1630-5. Epub 2012 Nov 20. Support Care Cancer. 2013. PMID: 23179489

3

Biomarkers for determining the prognosis in chronic myelogenous leukemia.

Sweet K, Zhang L, Pinilla-Ibarz J. Sweet K, et al. J Hematol Oncol. 2013 Jul 19;6:54. doi: 10.1186/1756-8722-6-54. J Hematol Oncol. 2013. PMID: 23870290 Free PMC article. Review.

4

The one-two punch: combination treatment in chronic myeloid leukemia.

Sweet KL, Hazlehurst LA, Pinilla-Ibarz J. Sweet KL, et al. Crit Rev Oncol Hematol. 2013 Dec;88(3):667-79. doi: 10.1016/j.critrevonc.2013.07.017. Epub 2013 Aug 20. Crit Rev Oncol Hematol. 2013. PMID: 23969231 Review.

5

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?

Sweet K, Oehler V. Sweet K, et al. Hematology Am Soc Hematol Educ Program. 2013;2013:184-8. doi: 10.1182/asheducation-2013.1.184. Hematology Am Soc Hematol Educ Program. 2013. PMID: 24319180 Review.

6

Novel therapeutics in acute myeloid leukemia.

Sweet K, Lancet JE. Sweet K, et al. Curr Hematol Malig Rep. 2014 Jun;9(2):109-17. doi: 10.1007/s11899-014-0199-0. Curr Hematol Malig Rep. 2014. PMID: 24633743 Review.

7

Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations.

Sweet K, Pinilla-Ibarz J, Zhang L. Sweet K, et al. Patient Prefer Adherence. 2014 Jul 8;8:981-6. doi: 10.2147/PPA.S53160. eCollection 2014. Patient Prefer Adherence. 2014. PMID: 25045255 Free PMC article. Review.

8

Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid leukemia.

Sweet K, Al Ali NH, Dalia SM, Komrokji RS, Crescentini RM, Tinsley S, Lancet JE, Papenhausen PR, Zhang L, Pinilla-Ibarz J. Sweet K, et al. Int J Hematol. 2014 Dec;100(6):567-74. doi: 10.1007/s12185-014-1685-9. Epub 2014 Oct 4. Int J Hematol. 2014. PMID: 25281405

9

Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia.

Pinilla-Ibarz J, Sweet K, Emole J, Fradley M. Pinilla-Ibarz J, et al. Among authors: sweet k. Anticancer Res. 2015 Dec;35(12):6355-64. Anticancer Res. 2015. PMID: 26637844 Review.

10

Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: An emerging clinical question.

Sweet K, Pinilla-Ibarz J. Sweet K, et al. Crit Rev Oncol Hematol. 2016 Jul;103:99-108. doi: 10.1016/j.critrevonc.2016.05.009. Epub 2016 May 14. Crit Rev Oncol Hematol. 2016. PMID: 27262540 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

296 results

Search Page

Filters